Literature DB >> 26139123

The promotion of salinomycin delivery to hepatocellular carcinoma cells through EGFR and CD133 aptamers conjugation by PLGA nanoparticles.

Jianxin Jiang1, Huaiwen Chen1,2, Chao Yu1, Yingying Zhang3, Meiyuan Chen1, She Tian1, Chengyi Sun1.   

Abstract

AIMS: To develop salinomycin-loaded poly(lactic-co-glycolic acid) nanoparticles conjugated with both CD133 aptamers A15 and EGFR aptamers CL4 (CESN), to target hepatocellular carcinoma (HCC) cells simultaneously expressing EGFR and CD133. MATERIALS &
METHODS: The antitumor activity and mechanism of CESN were investigated. RESULTS &
CONCLUSION: The cytotoxicity of CESN in HCC cells and CD133(+) HCC cells was superior to that of A15 or CL4-conjugted or nontargeted salinomycin-loaded nanoparticles. The antitumor assay in mice bearing HCC xenograft tumors confirmed the superior antitumor activity of CESN over other controls. We speculated that the improved therapeutic effect of CESN may be attributed to both targeting a higher percentage of HCC cells and increased delivery of salinomycin to HCC cells.

Entities:  

Keywords:  CD133; EGFR; hepatocellular carcinoma; nanoparticles; salinomycin

Mesh:

Substances:

Year:  2015        PMID: 26139123     DOI: 10.2217/nnm.15.43

Source DB:  PubMed          Journal:  Nanomedicine (Lond)        ISSN: 1743-5889            Impact factor:   5.307


  15 in total

Review 1.  Trends in the Design and Development of Specific Aptamers Against Peptides and Proteins.

Authors:  Maryam Tabarzad; Marzieh Jafari
Journal:  Protein J       Date:  2016-04       Impact factor: 2.371

Review 2.  Recent advances in hepatocellular carcinoma therapy.

Authors:  Rinku Dutta; Ram I Mahato
Journal:  Pharmacol Ther       Date:  2017-02-05       Impact factor: 12.310

3.  [Targeted killing of CD133+ lung cancer stem cells using paclitaxel-loaded PLGA-PEG nanoparticles with CD133 aptamers].

Authors:  L Pang; X Huang; L Zhu; H Xiao; M Li; H Guan; J Gao; H Jin
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-01-20

4.  The role of CD133 in hepatocellular carcinoma.

Authors:  Fengchao Liu; Yanzhi Qian
Journal:  Cancer Biol Ther       Date:  2021-04-25       Impact factor: 4.742

Review 5.  Ligand-based targeted therapy: a novel strategy for hepatocellular carcinoma.

Authors:  Min Li; Weiyue Zhang; Birong Wang; Yang Gao; Zifang Song; Qi Chang Zheng
Journal:  Int J Nanomedicine       Date:  2016-10-31

Review 6.  Aptamer-siRNA Chimeras: Discovery, Progress, and Future Prospects.

Authors:  Sven Kruspe; Paloma H Giangrande
Journal:  Biomedicines       Date:  2017-08-09

7.  Dual-modified cationic liposomes loaded with paclitaxel and survivin siRNA for targeted imaging and therapy of cancer stem cells in brain glioma.

Authors:  Xiyang Sun; Ying Chen; Hui Zhao; Guanglei Qiao; Meiyang Liu; Chunlei Zhang; Daxiang Cui; Lijun Ma
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

Review 8.  Recent insights in nanotechnology-based drugs and formulations designed for effective anti-cancer therapy.

Authors:  Ewelina Piktel; Katarzyna Niemirowicz; Marzena Wątek; Tomasz Wollny; Piotr Deptuła; Robert Bucki
Journal:  J Nanobiotechnology       Date:  2016-05-26       Impact factor: 10.435

Review 9.  Epithelial-to-mesenchymal plasticity of cancer stem cells: therapeutic targets in hepatocellular carcinoma.

Authors:  Aparna Jayachandran; Bijay Dhungel; Jason C Steel
Journal:  J Hematol Oncol       Date:  2016-08-30       Impact factor: 17.388

Review 10.  PLGA-Based Nanoparticles in Cancer Treatment.

Authors:  Sima Rezvantalab; Natascha Ingrid Drude; Mostafa Keshavarz Moraveji; Nihan Güvener; Emily Kate Koons; Yang Shi; Twan Lammers; Fabian Kiessling
Journal:  Front Pharmacol       Date:  2018-11-02       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.